STAT Plus: Pharmalittle: Hospitals criticize feds over remdesivir supplies; Moderna starting mid-stage Covid-19 vaccine trials soon
Hello, everyone, and how are you today? We are doing just fine, thank you, given…
Category: STAT Plus
STAT Plus: FTC approves AbbVie’s $63 million deal for Allergan amid scornful dissent
After months of deliberation, the Federal Trade Commission approved AbbVie’s (ABBV) $63 billion acquisition of…
STAT Plus: Pharmalittle: Gilead looks to widen access to remdesivir; ousted BARDA head files whistleblower complaint
Good morning, everyone, and welcome to the middle of the week. Hard to tell, though,…
STAT Plus: Taking a page from Apple, Fitbit launches a sweeping heart study
In a massive push to join Apple’s cardiac research ranks, Fitbit launched an ambitious study…
.jpg)
STAT Plus: Rebiotix unveils positive — but preliminary — data on its microbiome drug for C. diff infections
Rebiotix, one of a handful of major companies working on microbiome-based drugs, announced Wednesday that…
STAT Plus: Will employers still shell out for health tech benefits in an unemployment crisis? The industry is about to find out
It’s the oldest, most reliable strategy for building a business in health tech: Sell to…
STAT Plus: CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions
CytoDyn chief executive Nader Pourhassan’s lucrative sale of company stock was confirmed in a regulatory…
STAT Plus: Pharmalittle: WHO seeking wide access to remdesivir; Gavi proposes incentives for a Covid-19 vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: Akebia’s experimental pill meets anemia, heart-safety goals in two late-stage clinical trials
Akebia Therapeutics said Tuesday that its experimental anemia pill achieved the primary efficacy and heart-safety…
STAT Plus: Cellular ‘backpacks’ keep immune cells in attack mode against tumors
In a study recently published in Science Advances, Samir Mitragotri’s team at Harvard’s Wyss Institute…
STAT Plus: With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Never in modern times have such high hopes for millions of lives rested on one…
STAT Plus: Orphan drugs improve health — but aren’t priced cost-effectively, study finds
As regulators approve a growing number of orphan drugs, prices for these medicines, which treat small…
STAT Plus: With coronavirus pandemic, venture capitalists are taking extra precautions
Venture capital firms have billions of bucks in their bank accounts. In just the past…
STAT Plus: Pharmalittle: Roche wins emergency use nod for coronavirus antibody test; blood pressure drugs don’t raise infection risk
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT Plus: Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock
While Nader Pourhassan, the chief executive of drug maker CytoDyn, filed his intention to sell…
STAT Plus: Pharmalittle: Gilead faces remdesivir production challenges; will scientists run out of Covid-19 trial patients?
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: What value? High prices for dozens of cancer drugs aren’t tied to better clinical benefits
As payers increasingly demand good value for medicines, a new analysis found that costs for…
STAT Plus: Covid-19 is forcing smaller biotechs to cut spending and change financing plans
The Covid-19 pandemic is taking a harsh toll on small biotech companies, many of which…
STAT Plus: Researchers develop a non-invasive way to manipulate neurons to study behavior
A version of this article first ran in Morning Rounds, STAT’s newsletter offering a daily…
STAT Plus: Watchdog scolds HHS for lacking a big-picture plan to incentivize antibiotic development
Amid growing anxiety over a lack of antibiotics, a new report from a Congressional watchdog…
STAT Plus: Biogen’s blockbuster rare disease drug could be in trouble
The success of Biogen’s spinal muscular atrophy treatment Spinraza has been among the few bright…
.jpg)
STAT Plus: Patients, drug makers grapple with how to continue cancer trials during the coronavirus
The coronavirus pandemic has thrown a wrench into plans for hundreds of clinical trials seeking…
STAT Plus: For the first time, a blood test helped doctors find and treat cancers in seemingly healthy people
For the first time, doctors have used the results of a liquid biopsy test to…
STAT Plus: Off-the-shelf CAR-T therapy helps leukemia patients in a small, first-in-human trial
Scientists have created the first off-the-shelf CAR-T cells for a deadly form of adult leukemia,…
STAT Plus: China has near-total control of the world’s antibiotic supply. Is America at risk as a result?
WASHINGTON — The baby had so many pustules ravaging his face he could barely open…
STAT Plus: Most Americans believe Trump has failed to make progress lowering drug prices
More than one-third of U.S. adults believe that prescription drug prices have increased a lot…
STAT Plus: Vertex’s new cystic fibrosis drug needs to be far cheaper to be cost-effective, analysis finds
A newly approved treatment from Vertex Pharmaceuticals (VRTX) that targets roughly 90% of all cystic…
STAT Plus: ‘GI tract outside the body’ tests how well oral drugs are absorbed
When people swallow a pill, they expect the medicine to quickly reach the source of…
STAT Plus: Pharmalittle: Arthritis drug disappoints as a Covid-19 treatment; Pepcid is being tested to fight the coronavirus
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT Plus: Immunotherapy from Regeneron and Sanofi extends survival in non-small cell lung cancer
An immunotherapy from the drug firms Regeneron and Sanofi extended survival in previously untreated patients…
STAT Plus: New type of checkpoint inhibitor offers early promise against tumors, but will it last?
A new type of checkpoint inhibitor from an Israeli biotech company called Compugen is showing…
STAT Plus: Custom cell therapy shrinks lung tumors, seeding hope for a new cancer treatment
Tumors shrank in one quarter of patients with advanced lung cancer who received a bespoke…
STAT Plus: Gilead sues U.S., claiming it ‘secretly’ obtained patents on HIV research that led to Truvada
Gilead Sciences (GILD) has accused the U.S. government of breaching several contracts and “secretly” obtaining…
STAT Plus: Pharmalittle: Thousands sign up for trials studying hydroxycholoroquine; Gilead drug fails to help Covid-19 patients
And so, another working week will soon draw to a close. This may be hard…
STAT Plus: A gulf emerges in health tech: While some companies surge, others lay off their workers
You might expect them to be pandemic-proof: They’re the companies offering glimpses of the future…
STAT Plus: Sanofi MS drug reduced brain lesions in preliminary study
An experimental multiple sclerosis pill the drug giant Sanofi has touted as one of its…
STAT Plus: It started with a rumor. Now data show a drug is effective against graft-versus-host disease
Cancer patients inherit brand-new immune systems after undergoing bone marrow transplants. Though this intensive therapy…
STAT Plus: Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis
Biogen said Wednesday that the submission of a U.S. marketing application for its Alzheimer’s drug…
STAT Plus: On a 180-person video chat, biotech executives share the best ways do business amid the coronavirus
Given the hour — 4:30 a.m. in California, 7:30 a.m. in Boston — no one…
STAT Plus: FDA warns a company selling an insemination kit with parts only intended for use in animals
Trying to get pregnant can be challenging enough for anxious couples, but imagine being sold…
STAT Plus: Biogen execs have been quiet since Covid-19 spread through the biotech. The silence ends Wednesday
Do they go with a Covid-19 question? Or one about aducanumab? Maybe a combination of…
STAT Plus: Despite pricing controversies, pharma’s reputation is improving among patient groups
Even before the pandemic struck and drug makers were seen as potential saviors, the pharmaceutical…
STAT Plus: Despite evidence, many primary care doctors don’t want to prescribe medications for addiction
There are widely recommended medicines for treating opioid addiction, but one-third of primary care physicians…
STAT Plus: Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last
A pivot towards reselling Chinese-made coronavirus antibody tests in the U.S. has transformed tiny Aytu…
STAT Plus: Pharmalittle: Novartis to test hydroxycholoroquine in Covid-19; malaria drug failed to protect lupus patients from coronavirus
Good morning, everyone, and welcome to another working week. We hope the weekend offered something…
STAT Plus: Drug combination from Exelixis and Bristol-Myers Squibb extends survival in kidney cancer
A two-drug combination of Cabometyx, a once-daily pill, and Opdivo, an anti-cancer immunotherapy, improved the…
STAT Plus: After declining for years, anxiety and insomnia prescriptions start to climb
While prescriptions for antidepressants have climbed in the U.S. in recent years, those for anxiety…
STAT Plus: An FDA tool for hastening approvals is not very useful for breast cancer drugs
Nearly two years ago, the Food and Drug Administration published a table of surrogate endpoints…
STAT Plus: Dozens of financial firms want pharma to place Covid-19 patients over profits
More than three dozen asset managers, pension funds, and insurers are urging the pharmaceutical industry…
STAT Plus: Pharmalittle: Early data suggests Gilead Covid-19 drug works; did FDA drop standards too far in hunt for chloroquine?
And so, another working week will soon draw to a close. Not a moment too…